Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Intervention not reported
All cause mortality ‐ 30 days · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality ‐ 30 days (low certainty).
1 finding from 1 review
Intervention not reported
Bacteremia · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in bacteremia (moderate certainty).
1 finding from 1 review
Intervention not reported
Very wide CI · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Intervention not reported
Invasive fungal infection · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in invasive fungal infection (low certainty).
1 finding from 1 review
Intervention not reported
Episodes of febrile neutropenia · patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in episodes of febrile neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events requiring discontinuation of CSFs · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
It is very uncertain whether the intervention changes adverse events requiring discontinuation of CSFs (very low certainty).
1 finding from 1 review
Intervention not reported
All cause mortality ‐ End of · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality ‐ End of (low certainty).
1 finding from 1 review
Intervention not reported
All cause mortality subgroup analysis age>60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all cause mortality subgroup analysis age>60 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality subgroup analysis age< 60 · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all‐cause mortality subgroup analysis age< 60 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ‐ sensitivity analysis · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in all‐cause mortality ‐ sensitivity analysis (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia
The intervention showed no clear difference in overall survival (low certainty).
1 finding from 1 review
Intervention not reported
complete response · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in complete response (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease free survival · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in disease free survival (low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia
The intervention showed no clear difference in relapse rate (low certainty).
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab probably leads to lower infection with SARS‐CoV‐2 within 6 months compared with placebo (moderate certainty).
1 finding from 1 review
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower infection with SARS‐CoV‐2 within 6 monthsa compared with placebo (low certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (low certainty).
1 finding from 1 review